Abstract
Objectives: To clarify treatment patterns and outcomes for patients with unresectable or metastatic renal cell carcinoma in the molecular target therapy era in Japan. Methods: A multicenter, retrospective medical chart review study was carried out. Patients diagnosed with unresectable or metastatic renal cell carcinoma between January 2012 and August 2015 were enrolled. Data extracted from medical records included treatment duration, grade ≥3 adverse events, reason for discontinuation for each targeted therapy and survival data until August 2016. Results: Of 277 eligible patients, 266, 170 and 77 received first-, second- and third-line systemic treatment, respectively. Tyrosine kinase inhibitors were the most common first-line therapy (72.2%), followed by mammalian target of rapamycin inhibitors (14.3%) and cytokines (13.5%). Among 170 patients who received second-line treatment, tyrosine kinase inhibitor–tyrosine kinase inhibitor was the most common sequence (58.8%), followed by tyrosine kinase inhibitor–mammalian target of rapamycin inhibitor (14.1%) and cytokine–tyrosine kinase inhibitor (14.1%). With a median follow-up period of 19.8 months, median overall survival was not reached at 48 months. Patients who discontinued first-line tyrosine kinase inhibitors in <6 months showed poorer overall survival compared with patients who received first-line tyrosine kinase inhibitors for ≥6 months. Conclusions: The present analysis illustrates the contemporary treatment patterns and prognosis for patients with unresectable or metastatic renal cancer in a real-world setting in Japan. Tyrosine kinase inhibitor–tyrosine kinase inhibitor represents the most commonly used sequence. Shorter treatment duration of first-line tyrosine kinase inhibitors is associated with poorer prognosis, suggesting the need for better treatment options.
| Original language | English |
|---|---|
| Pages (from-to) | 202-210 |
| Number of pages | 9 |
| Journal | International Journal of Urology |
| Volume | 26 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 1 2019 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Urology
Cite this
Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan. / Harada, Kenichi; Nozawa, Masahiro; Uemura, Motohide; Tatsugami, Katsunori; Osawa, Takahiro; Yamana, Kazutoshi; Kimura, Go; Fujisawa, Masato; Nonomura, Norio; Eto, Masatoshi; Shinohara, Nobuo; Tomita, Yoshihiko; Kondo, Yukihiro; Ochi, Kenya; Anazawa, Yoshio; Uemura, Hirotsugu.
In: International Journal of Urology, Vol. 26, No. 2, 01.02.2019, p. 202-210.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan
AU - Harada, Kenichi
AU - Nozawa, Masahiro
AU - Uemura, Motohide
AU - Tatsugami, Katsunori
AU - Osawa, Takahiro
AU - Yamana, Kazutoshi
AU - Kimura, Go
AU - Fujisawa, Masato
AU - Nonomura, Norio
AU - Eto, Masatoshi
AU - Shinohara, Nobuo
AU - Tomita, Yoshihiko
AU - Kondo, Yukihiro
AU - Ochi, Kenya
AU - Anazawa, Yoshio
AU - Uemura, Hirotsugu
PY - 2019/2/1
Y1 - 2019/2/1
N2 - Objectives: To clarify treatment patterns and outcomes for patients with unresectable or metastatic renal cell carcinoma in the molecular target therapy era in Japan. Methods: A multicenter, retrospective medical chart review study was carried out. Patients diagnosed with unresectable or metastatic renal cell carcinoma between January 2012 and August 2015 were enrolled. Data extracted from medical records included treatment duration, grade ≥3 adverse events, reason for discontinuation for each targeted therapy and survival data until August 2016. Results: Of 277 eligible patients, 266, 170 and 77 received first-, second- and third-line systemic treatment, respectively. Tyrosine kinase inhibitors were the most common first-line therapy (72.2%), followed by mammalian target of rapamycin inhibitors (14.3%) and cytokines (13.5%). Among 170 patients who received second-line treatment, tyrosine kinase inhibitor–tyrosine kinase inhibitor was the most common sequence (58.8%), followed by tyrosine kinase inhibitor–mammalian target of rapamycin inhibitor (14.1%) and cytokine–tyrosine kinase inhibitor (14.1%). With a median follow-up period of 19.8 months, median overall survival was not reached at 48 months. Patients who discontinued first-line tyrosine kinase inhibitors in <6 months showed poorer overall survival compared with patients who received first-line tyrosine kinase inhibitors for ≥6 months. Conclusions: The present analysis illustrates the contemporary treatment patterns and prognosis for patients with unresectable or metastatic renal cancer in a real-world setting in Japan. Tyrosine kinase inhibitor–tyrosine kinase inhibitor represents the most commonly used sequence. Shorter treatment duration of first-line tyrosine kinase inhibitors is associated with poorer prognosis, suggesting the need for better treatment options.
AB - Objectives: To clarify treatment patterns and outcomes for patients with unresectable or metastatic renal cell carcinoma in the molecular target therapy era in Japan. Methods: A multicenter, retrospective medical chart review study was carried out. Patients diagnosed with unresectable or metastatic renal cell carcinoma between January 2012 and August 2015 were enrolled. Data extracted from medical records included treatment duration, grade ≥3 adverse events, reason for discontinuation for each targeted therapy and survival data until August 2016. Results: Of 277 eligible patients, 266, 170 and 77 received first-, second- and third-line systemic treatment, respectively. Tyrosine kinase inhibitors were the most common first-line therapy (72.2%), followed by mammalian target of rapamycin inhibitors (14.3%) and cytokines (13.5%). Among 170 patients who received second-line treatment, tyrosine kinase inhibitor–tyrosine kinase inhibitor was the most common sequence (58.8%), followed by tyrosine kinase inhibitor–mammalian target of rapamycin inhibitor (14.1%) and cytokine–tyrosine kinase inhibitor (14.1%). With a median follow-up period of 19.8 months, median overall survival was not reached at 48 months. Patients who discontinued first-line tyrosine kinase inhibitors in <6 months showed poorer overall survival compared with patients who received first-line tyrosine kinase inhibitors for ≥6 months. Conclusions: The present analysis illustrates the contemporary treatment patterns and prognosis for patients with unresectable or metastatic renal cancer in a real-world setting in Japan. Tyrosine kinase inhibitor–tyrosine kinase inhibitor represents the most commonly used sequence. Shorter treatment duration of first-line tyrosine kinase inhibitors is associated with poorer prognosis, suggesting the need for better treatment options.
UR - http://www.scopus.com/inward/record.url?scp=85055260269&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055260269&partnerID=8YFLogxK
U2 - 10.1111/iju.13830
DO - 10.1111/iju.13830
M3 - Article
C2 - 30345560
AN - SCOPUS:85055260269
VL - 26
SP - 202
EP - 210
JO - International Journal of Urology
JF - International Journal of Urology
SN - 0919-8172
IS - 2
ER -